News & Events

Read our latest news

March 8, 2023

Freya Pharma Solutions appoints Christa van Kan as Director Clinical Operations, governing the company’s upcoming confirmatory clinical development program using Lybrido against FSIAD

February 22, 2023

Freya Pharma Solutions’ innovative compound Lybrido for the treatment of Female Sexual Disorders well received at European Society for Sexual Medicine Congress

February 10, 2023

Freya Pharma Solutions extends its Scientific Advisory Board with USA-based international leading experts in the field of Female Sexual Disorders

February 2, 2023

Freya Pharma Solutions appoints Nicole Hijnen as President of the Board, overseeing the company’s upcoming clinical development program with LybridoTM against FSIAD

November 4, 2022

Freya Pharma Solutions: ALETTA Pivotal Trial Well Received at ISSM/SMSNA Scientific Meeting

September 28, 2022

Freya Pharma Solutions Receives Early EMA Scientific Advice on its upcoming Phase 3 Clinical Trial to Confirm Efficacy of Lybrido in Women Suffering From FSIAD

August 25, 2022

Freya Pharma Solutions Announced Further Strengthening of its IP Position for Improved Treatment for Women Suffering From FSIAD

June 29, 2022

Freya Pharma Solutions Announced Its Application for EMA Scientific Advice on its Phase 3 Clinical Trial to Confirm Efficacy of Lybrido in Women Suffering From FSIAD

May 25, 2022

Freya Pharma Solutions establishes Scientific Advisory Board with leading European experts in the field of female sexual disorders; Prof. Annamaria Giraldi, Prof. Rossella Nappi, Prof. Cobi Reisman, Prof. Linda Vignozzi and Dr. Giovanni Corona

April 12, 2022

Freya Pharma Solutions Announces Appointment of Dr. Jan van der Mooren as Chief Medical Officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD

March 29, 2022

Freya Pharma Solutions secures US$8.5 million enabling the start of a pivotal phase 3 trial with Lybrido against Female Sexual Interest/Arousal Disorder (FSIAD)

December 17, 2021

Freya Pharma Solutions to acquire all IP from Emotional Brain, giving opportunities to further examine pharmaceutical therapies for Female Sexual Interest/Arousal Disorder in a double blind, randomized phase 3 trial

Media coverage

Female sexual interest drug reaches tipping point with Phase III plans
Read more

a red and purple bed with a pillow in the centre written with

What women (still) want
Read more

Upcoming Events

25th European Society for Sexual Medicine (ESSM) Congress 2023

February 16-18, 2023 | Rotterdam, The Netherlands

28th Annual Scientific Program of the Sexual Medicine Society of North America (SMSNA)

April 28, 2023 | Chicago, USA

ICSM 2023: 17. International Conference on Sexual Medicine

August 17-18, 2023 | Kuala Lumpur, Malaysia

Nordic Association for Clinical Sexology (NACS) conference 2023

September 28 - October 1, 2023 | Oslo, Norway

International Society for the Study of Women’s Sexual Health (ISSWSH) Fall Course 2023

October 19-22, 2023 | Scottsdale, USA

24th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA)

November 16-19, 2023 | San Diego, USA

2023 Annual conference of the Society for the Scientific Study of Sexuality

November 16-19, 2023 | New Orleans, USA

24th World Meeting on Sexual Medicine - ISSM / MESSM Annual Scientific Meeting 2023

December 15-17, 2023 | Dubai, UAE

International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

February 22-25, 2024 | Long Beach, USA

Want to arrange a meeting?

Freya Pharma Solutions B.V.
Kraanspoor 50 | 1033 SE Amsterdam | The Netherlands

info@freyapharmasolutions.com

Freya Pharma Solutions B.V.
B.V. Kraanspoor 50 | 1033 SE Amsterdam | The Netherlands

info@freyapharmasolutions.com